Neos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD
20 déc. 2016 07h30 HE
|
Neos Therapeutics, Inc
DALLAS/FORT WORTH, Texas, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics to Present at BMO Prescription for Success Healthcare Conference
07 déc. 2016 08h00 HE
|
Neos Therapeutics, Inc
DALLAS/FORT WORTH, Texas, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
Neos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHD
17 nov. 2016 08h00 HE
|
Neos Therapeutics, Inc
DALLAS/FORT WORTH, Texas, Nov. 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
P2D Bioscience Lead ADHD Drug Demonstrates Efficacy in Preclinical Testing
12 avr. 2011 08h00 HE
|
P2D Bioscience
CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - Apr 12, 2011) - P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit/Hyperactivity Disorder...